Literature DB >> 9360927

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

D Finzi1, M Hermankova, T Pierson, L M Carruth, C Buck, R E Chaisson, T C Quinn, K Chadwick, J Margolick, R Brookmeyer, J Gallant, M Markowitz, D D Ho, D D Richman, R F Siliciano.   

Abstract

The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360927     DOI: 10.1126/science.278.5341.1295

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  1200 in total

1.  Specific therapy regimes could lead to long-term immunological control of HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

4.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro.

Authors:  C McCoig; G Van Dyke; C S Chou; L J Picker; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

7.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

8.  Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Authors:  N M Ferguson; F deWolf; A C Ghani; C Fraser; C A Donnelly; P Reiss; J M Lange; S A Danner; G P Garnett; J Goudsmit; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 9.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

10.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.